The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis (Q33402494)

26 July 2017

0 references

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis (English)

1 reference

26 July 2017

0 references

1 reference

Nick Freemantle

0 references

Hans-Juergen Moeller

1 reference

26 July 2017

Michael Bauer

1 reference

26 July 2017

Puvan Tharmanathan

series ordinal

1 reference

26 July 2017

Hans-Peter Volz

series ordinal

1 reference

26 July 2017

publication date

22 January 2009

1 reference

European Archives of Psychiatry and Clinical Neuroscience

26 July 2017

published in

1 reference

26 July 2017

volume

259

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

172-185

1 reference

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo

26 July 2017

cites work

1 reference

12 December 2020

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

1 reference

12 December 2020

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

12 December 2020

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 reference

12 December 2020

Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms

1 reference

12 December 2020

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

12 December 2020

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia

1 reference

12 December 2020

Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression

1 reference

12 December 2020

Extended-release venlafaxine in relapse prevention for patients with major depressive disorder

1 reference

12 December 2020

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

12 December 2020

Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients

1 reference

12 December 2020

Venlafaxine Versus Fluvoxamine in the Treatment of Delusional Depression

1 reference

12 December 2020

A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treat

1 reference

12 December 2020

Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder

1 reference

12 December 2020

Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia

1 reference

12 December 2020

A comparison of venlafaxine, trazodone, and placebo in major depression.

1 reference

12 December 2020

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

1 reference

12 December 2020

Efficacy and Safety of Venlafaxine ERvs.Amitriptyline ER in Patients with Major Depression of Moderate Severity

1 reference

12 December 2020

Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

12 December 2020

Venlafaxine versus placebo in the preventive treatment of recurrent major depression

1 reference

12 December 2020

Single-blind comparison of venlafaxine and nortriptyline in elderly major depression

1 reference

12 December 2020

Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

1 reference

12 December 2020

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study

1 reference

12 December 2020

Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

1 reference

12 December 2020

Efficacy of venlafaxine in depressive illness in general practice

1 reference

12 December 2020

A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression

1 reference

12 December 2020

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features

1 reference

12 December 2020

A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression

1 reference

12 December 2020

Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

12 December 2020

Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients

1 reference

12 December 2020

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

12 December 2020

Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.

1 reference

12 December 2020

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

12 December 2020

A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression

1 reference

12 December 2020

Trazodone and venlafaxine in treatment of depressive disorders

1 reference

12 December 2020

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

1 reference

12 December 2020

A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability

1 reference

12 December 2020

Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

1 reference

12 December 2020

A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients

1 reference

12 December 2020

Venlafaxine extended-release: a review of its use in the management of major depression

1 reference

12 December 2020

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

1 reference

12 December 2020

10.1007/S00406-008-0849-0

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1031067256

0 references

1 reference